RYONCIL
These highlights do not include all the information needed to use RYONCIL safely and effectively. See full prescribing information for RYONCIL. RYONCIL (remestemcel-L-rknd) suspension for intravenous infusion Initial U.S. Approval: December 2024
a4e0918f-7444-4694-adeb-d38d98345659
HUMAN PRESCRIPTION DRUG LABEL
Mar 3, 2025
Mesoblast
DUNS: 616697426
Products 8
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
remestemcel-l-rknd
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
remestemcel-l-rknd
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
remestemcel-l-rknd
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
remestemcel-l-rknd
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
remestemcel-l-rknd
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
remestemcel-l-rknd
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
remestemcel-l-rknd
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
remestemcel-l-rknd
Product Details
FDA regulatory identification and product classification information